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Background: We have shown that chronic obstructive pulmonary disease (COPD) is associated with increased
production of pro-inflammatory cytokines and the cytotoxic mediator, granzyme B by peripheral blood steroid
resistant CD28nullCD137 + CD8+ T cells and granzyme B by NKT-like and NK cells. We hypothesized that we could
target these pro-inflammatory/cytotoxic lymphocytes by inhibiting co-stimulation through CD137.
Methods: Isolated PBMC from patients with COPD and healthy controls were stimulated with phytohaemagglutinin
(PHA) ± blocking anti-CD137 ± 10−6 M methylprednislone (MP) (±stimulatory anti-CD137 ± control antibodies).
Pro-inflammatory cytokine profiles and expression of granzyme B, by T, NKT-like CD28 ± subsets and NK cells were
determined using flow cytometry.
Results: There was a significant decrease in the percentage of T, NKT-like subsets and NK cells producing IFNγ,
TNFα and granzyme B in all subjects in the presence of anti-CD137 blocking antibody compared with PHA alone
(eg, 60% decrease in CD8 + granzyme B + cells) or MP. Stimulatory anti-CD137 was associated with an increase in
the percentage of pro-inflammatory/cytotoxic cells. The inhibitory effect of anti-CD137 on IFNγ, TNFα and granzyme
B production by CD28null cells was greater than by CD28+ cells.
Conclusions: Blocking CD137 expression is associated with downregulation of IFNγ, TNFα and granzyme B by CD8+
T and NKT-like and NK cells. Targeting CD137 may have novel therapeutic implications for patients with COPD.
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Chronic obstructive pulmonary disease (COPD) is a leading
cause of death world wide. Existing treatments are largely
symptomatic and the only approved anti-inflammatory
medication, corticosteroids, has no proven disease modify-
ing effect [1]. The mechanisms underlying this resistance
are largely unknown, but suggest the presence of some self-
maintaining pathogenic process, probably initiated by
cigarette smoke, that prevents the normal resolution of the
inflammatory response [2]. Our group has reported in-
creased production of Th1 pro-inflammatory cytokines
IFN-γ and TNF-α by CD8+ T cells in peripheral blood and
lungs [3] and higher levels of the cytotoxic mediators* Correspondence: greg.hodge@health.sa.gov.au
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reproduction in any medium, provided the orgranzyme b and perforin in peripheral blood in current and
ex-smoker COPD patients compared to healthy smokers
and never-smokers [4].
Our previous studies have focused on identifying the
lymphocyte subset/s resistant to current therapeutics. We
have shown that COPD is associated with increased CD8/
CD28null cells in both current and ex-smoker COPD
groups and these cells expressed more IFNγ, CD137
(4-1BB), granzyme B and perforin when stimulated than
CD8 + CD28+ cells [5]. Using a mouse model of COPD, in
mice exposed to cigarette smoke for 12 weeks, CD8/
CD28null T-cells were significantly increased in the airway
with a trend for an increase in lung tissue and blood [5].
NKT-like cells are a small but important subset of lym-
phocytes expressing both T cell and NK cell markers. Re-
cently we also showed increased production of granzyme
B and decreased inhibitory receptor CD94 by peripheralLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Demographic details of the COPD and control
group
Subjects Controls COPD
No. of subjects 14 10
Age (years) 44 (±8) 58 (±16)*
FEV1, % pred 110.4 (±9) 60.5 (±20)
FEV1, % FVC 96 (±12) 58 (±15)*
Male/Female 8/6 6/4
Data showing mean ± SD.
Abbreviations: FEV1 forced expiratory volume in 1 second, FVC forced vital
capacity, *P < 0.05 compared to controls.
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NKT-like and NK cells were increased in bronchoalveolar
lavage (BAL) of COPD patients and this was associated
with increased NK cytotoxicity and decreased expres-
sion of the inhibitory receptor CD94 by both cell types
[6]. As signaling through NK-cell associated CD137 has
been shown to stimulate NK cell proliferation and IFNγ
production [7], we hypothesized that we could target
these pro-inflammatory/cyotoxic T, NKT-like and NK
cells in COPD by inhibiting co-stimulation through
CD137. Interestingly, we have recently shown that
NKT-like cells lose CD28 expression and up-regulate
CD137 following stimulation through the CD3 recep-
tor in lung transplant patients diagnosed with bron-
chiolitis obliterans syndrome [8].
To investigate this hypothesis, we determined whether
NKT-like and NK cells from COPD patients produce in-
creased levels of pro-inflammatory cytokines and whether
NKT-like cells up-regulate CD137 with concomitant loss of
CD28. To determine the effect of blocking co-stimulation
through CD137, isolated peripheral blood mononuclear
cells (PBMC) from COPD patients and healthy controls
were stimulated with phytohaemagglutinin (PHA) ± block-
ing anti-CD137 ± 10−6 M methylprednislone (MP) (±stimu-
latory anti-CD137 and isotyped matched control antibodies)
and cytokine profiles and granzyme B expression by T,
NKT-like and NK cells were determined using flow
cytometry.
Methods
Patient and control groups
COPD volunteers were specifically recruited for the study
and informed consent obtained. There was no exacerbation
of COPD for 6 weeks prior. Subjects with other co-existing
lung disease or aged greater than 75y were excluded. Ethics
approval was obtained from the Royal Adelaide Hospital
and the experiments were conducted with the understand-
ing and the written consent of each participant. COPD was
diagnosed using the GOLD criteria with clinical correlation
(Mild COPD: FEV1/FVC < 70% but FEV1 ≥ 80% predicted;
Moderate COPD FEV1 50% ≤ 80% predicted, Severe COPD
FEV1 30% ≤ 50% predicted, very severe COPD FEV1 < 30%)
[9]. Blood was collected from 10 patients with COPD
(Table 1) of whom all were ex-smokers (at least one year).
No patients were receiving oral GCS.
Blood was also obtained from 14 non-smoking volun-
teers (Table 1) with normal lung function. These were
healthy, recruited volunteers with no history of airways
disease. All subjects underwent spirometry as part of their
routine clinical assessment. Venous blood was collected
into 10 U/mL preservative free sodium heparin (DBL, Sydney,
Australia) and maintained at 4°C until processing. All pa-
tients were submitted to the same protocol and analysis
performed retrospectively.T, NKT-like and NK cell percentages
T, NKT-like and NK cell percentages in blood from
COPD patients and healthy controls were enumerated as
previously reported [10].
CD8 expression on NKT-like cells
We have previously shown an increase in CD8 +CD3+ T
cells in blood from COPD patients compared with healthy
controls. To enumerate CD8+ and CD8- subsets of NKT-
like cells, 150 μL aliquots of heparinised blood were
stained from COPD patients and healthy controls as previ-
ously reported [10].
CD137 expression on NKT-like and NK cells
We have previously shown loss of CD28 (ie, an increase
in the proportion of CD28null cells) and up-regulation
of CD137 on CD28 null T cells from blood in patients
with COPD compared with healthy controls [5].
CD137 is not constitutively expressed on T cells, but is
up-regulated following initial T-cell activation [11]. To de-
termine possible loss of CD28 and expression of CD137
on NKT-like and NK cells, 150 μL aliquots of blood were
stimulated with phorbol myristate (25 ng/mL) (Sigma,
Sydney, Australia) and ionomycin (1 μg/mL) (Sigma). Bre-
feldin A (10 μg/mL) was added as a “Golgi block” (Sigma)
to prevent shedding of CD137 and the tubes incubated
in a humidified 5% CO2/95% air atmosphere at 37°C [5].
Expression of CD137 was determination as previously re-
ported for T cells [5]. Briefly, at 16 h 100 μL 20 mM
EDTA/PBS was added to the culture tubes which were
vortexed vigorously for 20 sec to remove adherent cells.
Cells were permeabilized as described above. Two mL 0.5%
bovine serum albumin (Sigma/Aldrich, Sydney, Australia)/
Isoton II (Beckman Coulter, Sydney, Australia) was then
added and the tubes centrifuged at 300 × g for 5 min. After
decanting supernatant, Fc receptors were blocked with
10 μL human immunoglobulin (Intragam, CSL, Parkville,
Australia) for 10 min at room temperature. Five μL of ap-
propriately diluted anti- CD137 PE (BD), CD3 perCP.CY5.5
(BD), CD28 PE.CY7 (BD), CD56 APC (Beckman Coulter,
Sydney, Australia), CD8 APC.CY7 (BD) and CD45 V500
(BD) monoclonal antibodies were added for 15 min in the
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albumin (Sigma)/Isoton II (Beckman Coulter) was then
added and the tubes centrifuged at 300 × g for 5 min. After
decanting, cells were analyzed within 1 h on a FACSCanto
II flow cytometer using FACSDiva software (BD). Samples
were analyzed by gating lymphocytes using CD45 staining
versus side scatter (SSC). A minimum of 350,000 low SSC
events were acquired in list-mode format for analysis.
NKT-like cells were identified as CD3 +CD56+ CD45+ low
FSC/SSC events and NK cells as CD3-CD56+ CD45+ low
FSC/SSC events.
Granzyme B expression in CD28+ and CD28null
NKT-like cells
PBMC were isolated from blood by standard density gra-
dient centrifugation and cells re-suspended at 5 × 105 mL
in RPMI 1640 medium (Gibco, New York, USA) supple-
mented with 125 U/mL penicillin and 125 U/mL strepto-
mycin (Gibco). To investigate NKT-like cell production of
granzyme B, 150 uL of PBMC was added to FACS tubes.
Cells were permeabilised by addition of 0.5 mL 1:10 di-
luted FACSperm (BD) to each tube, mixed, and incubated
a further 10 min at room temperature in the dark. Two
mL 0.5% bovine serum albumin (Sigma) in IsoFlow
(Beckman Coulter) was then added and the tubes centri-
fuged at 300 × g for 5 min. After decanting supernatant, Fc
receptors were blocked with 10 μL human immunoglobu-
lin (Intragam, CSL, Parkville, Australia) for 10 min at room
temperature. Five μL of appropriately diluted granzyme B
FITC (BD), CD3 perCP.CY5.5 (BD), CD28 PE.CY7 (BD),
CD56 APC (Beckman Coulter, Sydney, Australia), CD8
APC.CY7 (BD) and CD45 V500 (BD) monoclonal anti-
bodies were added for 15 min in the dark at room
temperature. Cells were analyzed within 1 h on a FACSCa-
libur flow cytometer using CellQuest software (BD).
IFNγ and TNFα expression by NK cells and CD28+ and
CD28null NKT-like cells
Production of IFNγ and TNFα by CD28+ and CD28null
NKT-like cells was determined on blood samples from
all subjects as previously reported [8].
IFNγ and TNFα expression by CD137+ NK cells and CD137+
CD28+ and CD28null NKT-like cells
To determine if CD137 is expressed on NK and CD28+
and CD28null NKT-like cells that produce IFNγ and
TNFα (and hence potential targets of blocking CD137),
the percentage of these cells were determined from COPD
patients and controls as previously described [8].
Leucocyte stimulation with PHA ± antiCD137
To determine the effects of blocking co-stimulation
through CD137 on T cells, NKT-like and NK cells, PBMC
from COPD patients and control subjects were stimulatedwith 1 μg/mL PHA (Sigma, Sydney, Australia). For co-
stimulation blockade, PBMC were activated with 1 μg/mL
PHA alone or in the presence of 10 μg/mL purified block-
ing antibodies for CD137 (Biolegend, clone 4B4-1) and
isotype-matched control antibodies (eBioscience, Sydney,
Australia). Stimulation of T cells, NKT-like and NK cells
through CD137 was performed with 10 μg/mL stimulatory
antibodies for CD137 (R&D Systems, AF838).
T, NKT-like and NK cell cytokine and granzyme B production
following stimulation with PHA± blocking anti-CD137
On the 4th day post-activation with PHA ± blocking anti-
CD137, cultures were stimulated with phorbol myristate
(25 ng/mL) (Sigma, Sydney, Australia) and ionomycin
(1 μg/mL) (Sigma). Brefeldin A (10 μg/mL) was added as
a “Golgi block” (Sigma) and the tubes re-incubated in a
humidified 5% CO2/95% air atmosphere at 37°C for
16 h. Cytokine and granzyme B determination was per-
formed as previously reported [8]. Five μL of appropri-
ately diluted anti- IFNγ FITC (BD), granzyme B V450
(BD), CD137 PE (BD), CD3 perCP.CY5.5 (BD), CD28
PE.CY7 (BD), CD56 APC (Beckman Coulter, Sydney,
Australia), CD8 APC.CY7 (BD), TNFα V450 (BD) and
CD45 V500 (BD) monoclonal antibodies were added for
15 min in the dark at room temperature. Two mL of
0.5% bovine serum albumin (Sigma)/Isoton II (Beckman
Coulter) was then added and the tubes centrifuged at
300 × g for 5 min. After decanting, cells were analyzed
as above.
Effect of 10−6 M MP on T, NKT-like and NK cell cytokine
and granzyme B production following stimulation with
PHA ± blocking antiCD137
To determine the effects of 10−6 M MP on T and NKT-
like cell cytokine and granzyme B production following
stimulation, blood was stimulated with 1 μg/mL PHA
(Sigma) ±10−6 M MP± blocking antiCD137 for 4 days and
processed as above.
Statistical analysis
Statistical analysis was performed using the Mann–
Whitney test. Correlations were performed using Spearman
Rho correlation tests. SPSS software was applied and
differences between groups of p < 0.05 considered
significant.
Results
T, NKT-like and NK cell percentages
There were no significant changes in T, NKT-like or NK
cells in blood from patients with COPD compared with
control subjects (73 ± 12 and 76 ± 12% T cells (mean ± SD);
4.1 ± 4 and 3.5 ± 5% NKT-like cells; and 15.2 ± 5 and 10.5 ±
8% NK cells for COPD patients and control groups respect-
ively). There was no change in absolute numbers of
Hodge et al. BMC Pulmonary Medicine 2014, 14:85 Page 4 of 11
http://www.biomedcentral.com/1471-2466/14/85lymphocytes but there was an increase in the percentage
and absolute numbers of CD8 T cells and a decrease in the
percentage of CD4+ T cells in COPD patients compared
with control group consistent with our previous reports
[3-6,9,10] (data not shown).
CD8+ and CD8-CD28null NKT-like cells
There was a significant increase in the percentage of
CD8+ NKT-like cells in patients with COPD compared
with control subjects (59 ± 8 and 35 ± 6% (mean ± SD)
for COPD patients and control groups respectively).
There was a significant increase in the percentage of
CD28null/CD8+ NKT-like cells in patients with COPD
compared with control subjects (Figure 1) but no signifi-
cant change for CD28null/CD8- NKT-like cells between
groups (p > 0.05).
Granzyme B expression by CD28+ and CD28null NKT-like
cell subsets
We have shown that COPD is associated with an increase
in NKT-like cells producing granzyme B compared with
control subjects [6]. Cells were subsequently stained to de-
termine if CD28+ and/or CD28null NKT-like subsets are
associated with increased granzyme B expression. There
was a significant increase in the percentage of CD28null/
CD8 +NKT-like cells (but not CD28null/CD8- cells) ex-
pressing granzyme B in patients with COPD compared
with controls (Figure 2). There were no significant changes
























Figure 1 CD28nullCD8- (clear bars) and CD28nullCD8+ NKT-like cells
(C). Data presented as box plots. There was a significant increase in the pe
compared with control subjects but no change in CD28null/CD8- NKT-likesubsets expressing granzyme B between either group (p >
0.05 for all) (data not shown).
IFNγ and TNFα expression by CD28null and CD28+ NKT-
like cell subsets
We have shown an increase in the percentage of CD8 +
CD28null T cells producing IFNγ and TNFα in COPD
patients compared with healthy controls [5]. In the
current experiments, we determined if CD28+ and/or
CD28nullNKT-like subsets are associated with increased
IFNγ and TNFα production. CD28 expression was
unaltered on either CD8- or CD8 NKT-like cell subsets
following stimulation over this time period. There was
however a trend for an increase in the production of IFNγ
by CD28null/CD8+ NKT-like cells (but not CD28null/
CD8- NKT-like cells) in patients with COPD compared
with healthy controls (Figure 3).
There was an increase in the percentage of CD28null/
CD8+ NKT-like cells producing TNFα in patients with
COPD compared with healthy controls (Figure 4). There
were no significant changes in the percentage of CD28+/CD8-
or CD28+/CD8+ producing IFNγ or TNFα between any
of the groups studied (p > .05 for all) (data not shown).
CD137 expression on NK cells and CD28null and CD28+
NKT-like cell subsets following stimulation
We have reported a loss of CD28 and up-regulation of
CD137 on CD28null T cells in patients with COPD com-
pared with healthy controls [5] findings consistent with theN C
ct Group
P=0.013
(grey bars) in 10 control subjects (N) and 14 patients with COPD
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Figure 2 CD28nullCD8- (clear bars) and CD28nullCD8+ NKT-like cells (grey bars) producing granzyme B (GB+) in 10 control subjects
(N) and 14 patients with COPD (C). Data presented as box plots. There was a significant increase in the percentage of CD28null/CD8 NKT-like




























Figure 3 CD28nullCD8- (clear bars) and CD28nullCD8+ NKT-like cells (grey bars) producing IFNγ in 10 control subjects (N) and 14
patients with COPD (C). Data presented as box plots. There was a trend for an increase in the percentage of CD28null/CD8+ NKT-like cells
producing IFNγ in patients with COPD compared with control subjects.
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Figure 4 CD28nullCD8- (clear bars) and CD28nullCD8+ NKT-like
cells (grey bars) producing TNFα in 10 control subjects (N) and
14 patients with COPD (C). Data presented as box plots. There was
a significant increase in the percentage of CD28null/CD8+ NKT-like




























Figure 5 CD28nullCD137 + CD8- (clear bars) and CD28nullCD137 + CD
patients with COPD (C). Data presented as box plots. There were no sign
subsets between any of the groups (p > 0.05 for all).
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CD137 is expressed on NK cells and if there is a similar loss
of CD28 and up-regulation of CD137 on NKT-like cells,
blood was stimulated and processed as previously reported
[5]. There was no difference in CD137 expression on
CD28null or CD28+ CD8- or CD8+ NKT-like cells between
the various groups studied (Figure 5.) There was however a
significant increase in the co-expression of CD137 and gran-
zyme B (Figure 6), a trend for an increase in CD137 and
IFNγ (Figure 7) and a significant increase in CD137 and
TNFα (Figure 8) in patients with COPD compared with con-
trols. Representative plots of CD28nullCD8+CD137 +
NKT-like cells producing TNFα from a control subject and
a patient with COPD are shown in Figure 9. There were no
significant changes in the percentage of CD28+/CD8-/
CD137+ or CD28+/CD8+/CD137+ NKT-like cells produ-
cing granzyme B, IFNγ or TNFα between either group stud-
ied (p > .05 for all) (data not shown). There was no
significant change in the expression of CD137 on NK cells
between COPD patients and control subjects (91 ± 7
and 87 ± 12% (mean ± sd) CD137 +NK cells for COPD
patients and controls respectively). There was however a
significant increase in CD137 +Granzyme b + expression
in NK cells in COPD patients compared with control sub-
jects (91 ± 8 and 62 ± 14% (mean ± sd) CD137 +GB +NK
cells for COPD patients and controls respectively) but not
CD137 + IFNγ +NK cells or CD137 + TNFα +NK cells
(data not shown).N C
ct Group
8+ NKT-like cells (grey bars) in 10 control subjects (N) and 14






























Figure 6 CD28nullCD137 + CD8- (clear bars) and
CD28nullCD137 + CD8+ NKT-like cells (grey bars) producing
granzyme B in 10 control subjects (N) and 14 patients with
COPD (C). Data presented as box plots. There was a significant
increase in CD28nullCD137 + CD8+ NKT-like cells producing






























Figure 8 CD28nullCD137 + CD8- (clear bars) and
CD28nullCD137 + CD8+ NKT-like cells (grey bars) producing
TNFα in 10 control subjects (N) and 14 patients with COPD (C).
Data presented as box plots. There was a trend for an increase in
CD28nullCD137 + CD8+ NKT-like cells producing TNFα in patients
with COPD compared with control subjects.
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b, IFNγ and TNFα expression by CD28null/CD28+ T
cell subsets
Having shown a loss of CD28 and up-regulation of CD137
on CD28null T cells in patients with COPD compared
































Figure 7 CD28nullCD137 + CD8- (clear bars) and
CD28nullCD137 + CD8+ NKT-like cells (grey bars) producing
IFNγ in 10 control subjects (N) and 14 patients with COPD (C).
Data presented as box plots. There was a trend for an increase in
CD28nullCD137 + CD8+ NKT-like cells producing IFNγ in patients
with COPD compared with control subjects.effect of blocking antibody to CD137 on granzyme B ex-
pression and IFNγ and TNFα production by NK cells and
CD28nullCD8- and CD28nullCD8+ T cells and NKT-like
cells. The inhibitory effect of blocking anti-CD137 was sig-
nificantly greater than for 10−6 M MP and CD28nullCD8+
and CD8- subsets than for CD28 + CD8+ and CD8- sub-
sets for granzyme B, IFNγ and TNFα. Data for CD8+
T cells shown in Table 2. Data for CD8- T cells not shown.
The inhibitory effect of blocking anti-CD137 and MP on
granzyme B, IFNγ and TNFα expression was additive.
Inhibitory effect of blocking anti-CD137 ±MP on granzyme
b, IFNγ and TNFα expression by CD28null/CD28+ NKT-like
cell subsets
The inhibitory effects of blocking anti-CD137 on granzyme
B, IFNγ and TNFα expression by CD28null and CD28+
NKT-like cell subsets were similar to those for CD28null
and CD28+ T cell subsets (Table 3). The inhibitory effect
of blocking anti-CD137 was significantly greater than for
CD28nullCD8+ and CD8- subsets than for CD28 +CD8+
and CD8- subsets for granzyme B, IFNγ and TNFα. Data
for CD8+ NKT-like cells shown in Table 3. Data for CD8-
NKT-like cells not shown. The inhibitory effect of blocking
anti-CD137 and 10−6 M MP on granzyme b, IFNγ and
TNFα expression was additive.
Inhibitory effect of blocking anti-CD137 ±MP on
granzyme b, IFNγ and TNFα expression by NK cells
The inhibitory effects of blocking anti-CD137 on gran-



















Figure 9 Representative plots of CD28nullCD137 + CD8 +NKT-like cells producing TNFα from a control subject and a patient with COPD.
There was a significant increase in CD28nullCD137 + CD8+ NKT-like cells producing TNFα in patients with COPD compared with control subjects.
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and TNFα by NK cells was significantly greater than for
Granzyme B and significantly greater than the effect of
MP on T and NKT-like IFNγ and TNFα expression.
Effect of stimulatory anti-CD137 antibodies on granzyme
b, IFNγ and TNFα expression by NK cells and CD28null/
CD28+ T cells and NKT-like cell subsets
Granzyme b, IFNγ and TNFα production by NK cells and
CD28null and CD28+ T cells and NKT-like cell subsets
was significantly increased in the presence of stimulatory
anti-CD137 antibodies compared with control antibody eg.,
31 ± 7% and 22 ± 5% increase in TNFα by CD28nullCD8+
and CD28 +CD8+ Tcells respectively.Table 2 The inhibitory effect of anti-CD137 blocking
antibody (10 μg/mL) (a137), 10−6 M methylprednisolone
(MP) alone and in combination on granzyme B, IFNγ and
TNFα expression by CD28null(28-) and CD28+ (28+) CD8+ T
cells following stimulation (mean ± SEM of 8 experiments)
compared with control antibody
Granzyme B IFNγ TNFα
CD8+ CD8+ CD8+
28- 28+ 28- 28+ 28- 28+
a137 26 ± 4* 17 ± 3 28 ± 3* 21 ± 2 31* ± 5 23 ± 2
MP 2 ± 1 5 ± 2 2 ± 1 5 ± 2 1 ± 1 4 ± 2
a137 +MP 29 ± 3# 21 ± 3# 31 ± 3# 26 ± 3# 32 ± 3# 27 ± 3#
*The percentage inhibition of granzyme B, IFNγ and TNFα by CD28- and CD28+T
cells compared with control (same specimen) without treatment/s.
The inhibitory effect of anti-CD137 was greater than for MP for granzyme B,
IFNγ and TNFα in all T-cell subsets (p < 0.05 for all).
*The inhibitory effect of anti-CD137 was greater than for the CD28nullCD8+
subset than for the CD28 + CD8+ subset for granzyme B, IFNγ and TNFα
(p < 0.05 for all).
#The combination of anti-CD137 and 10−6 M methylprednisolone resulted in
the additive inhibition of granzyme B, IFNγ and TNFα expression in CD28null
and CD28+ CD8+ T cells.Discussion
In this study we show that COPD is associated with in-
creased pro-inflammatory cytokine production by periph-
eral blood NK and NKT-like cells. We have previously
shown that COPD is associated with increased granzyme
B in peripheral blood NK and NKT-like cells and our
current study extends these findings to show that these
cells are both pro-inflammatory and cytotoxic [6]. Further-
more, down-regulation of CD28 on CD8+ NKT-like cells
was associated with the most pro-inflammatroy/cytotoxic
subset of these cells, a finding similar to that previously
shown for CD28nullCD8+ T cells in patients with COPD
[5]. Persistent antigenic stimulation has been shown to
progressively and irreversibly down-regulate CD28 expres-
sion on CD8+ T cells [12]. Our new findings indicate that
down-regulation of CD28 and up-regulation of CD137 is
associated with increased pro-inflammatory cytokines and
granzyme B production by CD8+ NKT-like cells. Further-
more, expression of CD137 on NK cells was associated
with increased granzyme B by this lymphocyte subset.
CD137 has previously been shown to be a stimulatory
receptor for NK cells resulting in IFNγ production [7].
Signaling through NK cells-associated CD137 promoted
helper function for CD8+ cytolytic T cells and may be
involved in the crosstalk between innate and adaptive
immunity [7]. Current therapeutics fail to inhibit these
cytotoxic, pro-inflammatory molecules known to be asso-
ciated with the disease process in COPD and our findings
of a non-significant decrease in these molecules in CD8 +
T and CD8 +NKT-like cells in the presence of MP con-
firm these clinical findings. In contrast, there was a signifi-
cant decrease in IFNγ and TNFα by NK cells in the
presence of MP compared with blocking anti-CD137 sug-
gesting treatment with MP alone may be adequate at inhi-
biting these pro-inflammatory cytokines by NK cells.
Table 3 The inhibitory effect of anti-CD137 blocking antibody (10 μg/mL) (a137), 10−6 M methylprednisolone (MP)
alone and in combination on granzyme B, IFNγ and TNFα expression by CD28null(28-) and CD28 + (28+) CD8+ NKT-like
cells and NK cells following stimulation of PBMC from COPD patients (mean ± SEM, mean of 8 experiments) compared
with control antibody
Granzyme B IFNγ TNFα
CD8 + NKT-like NK CD8 + NKT-like NK CD8 + NKT-like NK
28- 28+ 28- 28+ 28- 28-
a137 21 ± 2* 14 ± 2 14 ± 2 26 ± 3* 20 ± 3 22 ± 3 30* ± 4 23* ± 4 24 ± 3
MP 1 ± 1 3 ± 2 2 ± 2 2 ± 1 5 ± 6 43 ± 3^ 2 ± 1 2 ± 1 47 ± 9^
a137 +MP 22 ± 4# 17 ± 3# 15 ± 3# 28 ± 3# 25 ± 2# 66 ± 3 32 ± 4# 25 ± 4# 70 ± 7#
*The percentage inhibition of granzyme B, IFNγ and TNFα by CD28- and CD28+ NKT-like and NK cells compared with control (same specimen) without treatment/s.
The inhibitory effect of anti-CD137 was greater than for MP for granzyme B, IFNγ and TNFα in all NKT-like cell subsets (p < 0.05 for all).
*The inhibitory effect of anti-CD137 was greater than for the CD28nullCD8+ NKT-like subset than for the CD28 + CD8+ NKT-like subset for granzyme B, IFNγ and
TNFα (p < 0.05 for all). ^The inhibitory effect of MP on IFNγ and TNFα by NK cells was significantly greater than for Granzyme B (p < 0.05) and significantly greater
than the effect of anti-CD137.
#The combination of anti-CD137 and 10−6 M methylprednisolone resulted in the additive inhibition of granzyme B, IFNγ and TNFα expression in CD28null and
CD28+ CD8+ NKT-like cells and NK cells.
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crease in IFNγ production by isolated NK cells from
COPD patients in the presence of budesonide [11]. The
additive effect of MP with blocking anti-CD137 possibly
reflects the different mechanisms of action of these two
therapeutics, MP acting through the steroid receptor and
anti-CD137 targeting the surface co-stimulatory molecule
on these cells. Our findings of increased CD137 expres-
sion on NK cells and CD28null NKT-like cells and similar
findings for CD28null T-cell subsets [5] allowed us to ex-
plore whether blocking this co-stimulatory receptor would
be effective at inhibiting downstream effector mechanisms
in all these pro-inflammatory/cytotoxic lymphocyte sub-
groups. Co-stimulatory signals through CD137 have been
shown to preferentially induce CD8+ T cell proliferation
and lead to the amplification of the cytotoxic T cell re-
sponse [12] and may explain our previous and current find-
ings for increased CD8+ cytotoxic cells compared with
CD4+ T cell (and NKT-like cell) subsets. Pro-inflammatory
cytokines, in particular TNFα may be the driving force be-
hind COPD [13]. T-cell derived TNFα has been shown to
cause apoptosis of airway epithelial cells and impair the
clearance of these cells by alveolar macrophages [14]. We
and others have shown that uncleared apoptotic material in
the COPD airway can undergo secondary necrosis and thus
perpetuate inflammation and this problem persists after
smoking cessation [15]. TNFα has also been shown to in-
duce IL-2Rs and IFNγ production by T cells and activate
neutrophils, macrophages, endothelial cells and fibroblasts
[16]; cells that play important roles in the pathogenesis of
COPD [2]. Recently it has been shown that fractalkine, a
potent chemoattractant for monocytes and T cells pro-
duced by airway smooth muscle cells, was induced in the
presence of both IFNγ and TNFα [17].
These pro-inflammatory molecules may play a role
in the systemic effects of the disease and associated
co-morbidities such as cardiovascular disease, diabetes,osteoporosis and peptic ulceration [13]. Inhaled cortico-
steroids have major benefits for the treatment of airway
inflammation in asthma but the reason for their relative
lack of efficacy in COPD is both poorly understood and a
major limiting factor in COPD treatment. Hence new ef-
fective treatments are urgently needed to help this devas-
tating, widespread disease [2].
Blocking co-stimulation through CD137 resulted in a
modest but significant reduction in these cytotoxic/pro-in-
flammatory molecules compared with MP alone, hence a
more targeted approach with blocking anti-CD137 may
prove more efficacious in treating patients with COPD
where the use of corticosteroids has no proven disease
modifying effect [2].
T cells have been shown to migrate to the lung and re-
enter the circulation and as such, these cytotoxic cells
identified in the peripheral blood of these patients may be
reflective of cell populations in the lungs of these patients
[18]. A study examining the presence of these pro-
inflammatory cells T, NKT-like and NK cells in the air-
ways and in intra-epithelial cells lining the lungs from
these patients, as we have previously done for BAL [3] and
bronchial brushings [19] would be an important addition
to these studies. Furthermore, similar studies of current
smokers with and without COPD may elucidate the effect
of smoking on these pro-inflammatory/cytotoxic subsets.
In the mouse model, there have been several reports of
blockade of the CD137 (4-1BB) pathway improving arthero-
sclerosis [20] and autoimmune inflammation [21]. CD137-
directed NK/NKT cells play an important role in the
inflammatory response leading to the production of pro-
inflammatory cytokines and cytolytic activity in septic shock
[22] indicating efficacy and safety in the animal model. Fur-
thermore, mice that were deficient in CD137 had substan-
tially reduced levels of IFNγ and TNFαmRNA.
Interestingly, our findings show that these cytotoxic
NK cells, and pro-inflammatory/cytotoxic CD28null T
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albeit in reduced numbers to patients with COPD. These
CD28null cells may also be responsible for other inflam-
matory conditions such as rheumatoid arthritis [23],
cardiovascular disease [24], end-stage renal disease [25]
and ulcerative colitis [26]. CD28null cells have also been
reported in autoimmune disease where CD4 + CD28null
cells were not susceptible to the regulatory effects of regu-
latory T cells [27], results similar to our own unpublished
findings. This is an important point and may help explain
the lack of regulatory control of these cells in all these in-
flammatory diseases. As such, these diseases may all bene-
fit from our findings of therapeutic targeting of CD137.
Furthermore monitoring response using these assays may
offer a rapid indication of treatment efficacy.
Conclusion
In conclusion, blocking CD137 expression in T, NKT-like
and NK cells is associated with downregulation of IFNγ,
TNFα and granzyme B and may have novel therapeutic
implications for patients with COPD where current strat-
egies are inadequate.
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